Policy / Pricing FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results FDAThe U.S.Policy / PricingRead full story pharminent April 13, 2026 (Last updated: April 14, 2026) FDA The U.S. Policy / PricingRead full story Post navigation Previous: USP adds Tamiflu, Trulicity to vulnerable list as upstream analysis reshapes supply concernsNext: Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma Related Stories Policy / Pricing Mid-cap biotechs join Trump’s latest round of drug pricing deals pharminent September 1, 2026 Policy / Pricing MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones pharminent August 27, 2026 Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026